Bespak is increasing pressurized metered dose inhaler manufacturing capacity to support Chiesi Group’s Carbon Minimal Inhaler (CMI) program.

Kenox Pharmaceuticals Inc. (Kenox), a fast‑growing contract development and manufacturing organization (CDMO) dedicated exclusively to Orally Inhaled and Nasal Drug Products (OINDPs) and Ophthalmic ...

A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly half-a-billion-dollar investment from Italian drugmaker Chiesi. As part of an ongoing ...

Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and ...

Joining drugmakers like AstraZeneca and Novo Nordisk, GSK is making big strides in its quest to clean up its carbon footprint. GSK plans to start late-stage trials of a low-carbon version of its ...

Two Minneapolis-based companies – digital health care management program maker HealthFactors and medical-focused R&D firm Koronis BioMedical Technologies (KBT) – are working together to create new ...

Process development is the exercise of creating new and improved manufacturing methods, optimizing them in terms of time and financial efficiency while maintaining regulatory compliance and product ...

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...